CytRx cancels a Phase II trial

CytRx Corp. (CYTR) said it has stopped a Phase II trial of RheothRx in heart attack patients ineligible to receive thrombolytics after enrolling 200 of 250 planned patients because of data showing an unusual incidence of acute

Read the full 378 word article

How to gain access

Continue reading with a
two-week free trial.